Neurizon Therapeutics (ASX: NUZ) said high levels of its drug candidate NUZ-001 and its major active Sulfone metabolite crossed the blood-brain barrier in a rodent preclinical pharmacokinetic study, according to a Friday Australian bourse filing.
They achieved brain concentrations consistent with those shown to reverse pathological transactive response DNA-binding protein 43 aggregation in patient-derived induced pluripotent stem cells.
The ability of therapeutics to access the central nervous system remains a major barrier in the treatment of neurodegenerative diseases such as amyotrophic lateral sclerosis. Transactive response DNA-binding protein 43 is a known driver of amyotrophic lateral sclerosis pathology.
NUZ-001 and its sulfone metabolite significantly prevented the aggregation of transactive response DNA-binding protein 43 in M337V motor neurons treated simultaneously with the proteasomal stressor at all concentrations tested.
The firm's shares fell 3% on market close.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。